Global Coalition for Adaptive Research
  • Leadership
  • GBM AGILE
    • About GBM AGILE
    • GBM AGILE Trial Sites
    • FAQs
    • Strategic Partners
  • REMAP-COVID
    • About REMAP-COVID
    • REMAP-COVID US Trial Sites
  • Ovarian CanceRx
  • News
  • Join Us
  • Contact
  • DONATE
Global Coalition for Adaptive Research

Our mission is to speed the
discovery and development of
treatments for patients with
rare and deadly diseases.

OVARIAN CANCERX

Info     Press release

REMAP-COVID: Now Enrolling

Info     Latest Results from REMAP

GBM AGILE: Now Enrolling

Info     Press release

INITIAL GOALS

Operationalize GBM AGILE into a self-sustaining
engine of therapeutic and biomarker development
for patients with GBM.
Finance the launch and ongoing activity of new
GBM-focused therapies developed through
GBM AGILE.
Use GBM AGILE as a model for developing an efficient
framework for the discovery and development of
therapies and biomarkers for other rare and deadly diseases.
Randall Garnick Photography, National Brain Tumor Society

LEADERSHIP

The Global Coalition for Adaptive Research (GCAR) is an international partnership


The Global Coalition for Adaptive Research (GCAR) is an international partnership comprised of some of the world’s foremost clinical, translational, and basic science investigators. Through this collaboration and open exchange of ideas, the ultimate beneficiary—the patient—is supported in the fight against rare and deadly diseases.

READ MORE

GBM AGILE is a seamless Phase II (Efficacy and Safety) / Phase III (Confirmatory) trial to identify effective therapies and the most promising biomarker-defined populations for those therapies in patients with glioblastoma.

GBM AGILE is changing the IDEA of clinical trials

Innovative – Next-generation trial that will lower cost of development and speed progress.

Dynamic – Perpetual learning system to quickly add potentially promising new drugs and drop those that appear to be ineffective.

Efficient – Design and trial structure that will require fewer patients and a shorter time frame to get important answers about a drug's effectiveness.

Accessible – Global effort open to a broad patient population of newly diagnosed and recurrent GBM patients.
LEARN MORE

NEWS


Cure Brain Cancer Foundation invests in GBM AGILE, connecting Australians to an innovative clinical trial program to treat glioblastoma
FEBRUARY 22, 2022  |  CURE BRAIN CANCER FOUNDATION
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
JANUARY 18, 2022  |  BUSINESSWIRE
Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma
NOVEMBER 30, 2021  |  PRNEWSWIRE
GBM AGILE Opens to Paxalisib in Canada
NOVEMBER 29, 2021  |  KAZIA THERAPEUTICS
Ovarian CanceRx: New Innovative Clinical Research Effort Seeks to Accelerate the Development of New Treatments for Deadliest Gynecological Cancer
SEPTEMBER 23, 2021  |  BUSINESSWIRE
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
AUGUST 4, 2021  |  NEJM
Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Apremilast in REMAP-COVID
July 12, 2021  |  BUSINESSWIRE
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
FEBRUARY 25, 2021  |  NEJM
Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma
FEBRUARY 3, 2021  |  NEWSWISE
Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system—lessons learned and recommendations
JANUARY 28, 2021  |  BIOMED CENTRAL
ALL NEWS

GET INVOLVED

MAKE A DONATION
STAY CONNECTED
SUBSCRIBE NOW!
×

Subscribe to our mailing list

* indicates required
I am a:

CONTACT US

For additional information about GCAR and to learn how you can collaborate with us, please contact:
GENERAL INQUIRIES
MEDIA INQUIRIES
Copyright © 2022  Global Coalition for Adaptive Research. All Rights Reserved. 617-299-6471
The Global Coalition for Adaptive Research is registered as a 501(c)(3) nonprofit organization. Contributions to the Global Coalition for Adaptive Research are tax-deductible to the extent permitted by law.
Privacy  •  Design by Mintwich Creative  •  Development by Example 7
  • Home
  • Leadership
  • About REMAP-COVID
  • REMAP-COVID US Trial Sites
  • Ovarian CanceRx
  • GBM AGILE
  • About GBM AGILE
  • GBM AGILE Trial Sites
  • FAQs
  • Strategic Partners
  • News
  • Join Us
  • Contact
  • DONATE